Our goal is to provide you with the most up to date, comprehensive and accurate medical information related to CLOVES Syndrome.
All medical material on this website is developed with oversight and direction from CLOVES Syndrome Community’s Scientific and Medical Advisory Board (SMAB).
Guillaume Canaud is a MD, PhD working at Renal Division of Necker Hospital in Paris. He did his medical school in Montpellier and moved to Paris in 2002 to perform his Residency in Nephrology (2002 to 2007). He became Senior Resident at Renal Division of Necker Enfants Malades (Prof. Legendre) in 2007. He spent four years from to 2008 to 2012 in the laboratory of Dr. Fabiola Terzi (INSERM U1151, Necker Enfants Malades Hospital), where he obtained his PhD degree in molecular and cellular biology. Then, as postdoctoral fellow, he joined the Joseph Bonventre’s Laboratory (Harvard Medical School) from 2012 to 2014 developing a project on the molecular mechanisms of chronic kidney disease progression. He rejoined Prof. Legendre’s team as Associate Professor in 2014 and opened his own research group dedicated to translational medicine. He obtained a very competitive European Research Council (ERC) starting grant (2015) for his research project on kidney and an ERC Proof of Concept Grant for his translational research proposal in rare diseases (2016).
Recently, Guillaume and his group, identified and reported in Nature a very promising therapeutic strategy for patients with a rare genetic disorder called PIK3CA-Related Overgrowth Syndrome. He published his work as first or last author in top leading medical and scientific journals such as Nature, The New England Journal of Medicine, Nature Medicine, Science Translational Medicine or Proceedings National of the American Science. He is the inventor of 10 patents, and received numerous awards including the Prize Jean Lecocq of the French Academy of Sciences (2018), the Jean Hamburger Prize from the City of Paris (2019) and the Eloi Collery Prize from the French Academy of Medicine (2019, highest distinction).
In 2019, Guillaume became full Professor of Medicine at Necker Hospital/University Paris Descartes and created the first multidisciplinary unit dedicated to patients with overgrowth syndromes. In addition, he launched a private/public consortium (acronym COSY: Cure Overgrowth SYndromes) to improve the care and outcome of patients with overgrowth syndrome that was awarded with 9.4 M€ grant from the French government.
Kim M. Keppler-Noreuil, MD
Professor of Pediatrics, George Washington University School of Medicine and Health Sciences
Attending Physician/ Clinical Genetics
Rare Disease Institute – Genetics and Metabolism
Children’s National Medical Center
Kim Keppler-Noreuil, MD joined the Division of Genetics and Metabolism, Rare Disease Institute at Children’s National Medical Center as Professor of Pediatrics in November 2018 after her tenure at the National Human Genome Research Institute/National Institutes of Health as Clinician Associate Investigator from 2012-2018. Dr. Keppler-Noreuil completed her pediatric residency at the Arkansas Children’s Hospital, University of Arkansas for Medical Science, and her fellowship in Medical Genetics in the Department of Pediatrics, University of Alabama. She was on faculty as Professor of Pediatrics, Division of Medical Genetics at the University of Iowa Hospitals & Clinics, Clinical Director of the Iowa Registry of Inherited and Congenital Defects, and Program Director of the Medical Genetics Residency Training Program up to 2012. She also served as Co-Director of the Medical Genetics Course for the first-year medical students. She has been actively involved in patient care, teaching and clinical research during her career.
Dr. Keppler-Noreuil’s clinical and research interests have included clinical delineation of multiple malformation syndromes, and studies of epidemiology and pathogenesis of birth defects, inherited and chromosomal disorders. As the Clinical Director of Birth Defects, Iowa Registry for Congenital & Inherited Disorders (IRCID) from 1997-2012, she oversaw cases ascertained by the IRCID, and as Co-Investigator contributed to the development of case classification guidelines for the National Birth Defect Prevention Study (NBDPS), a multicenter study of genetic and environmental risk factor of over 30 major birth defects, as well as being the reviewer /classifier for NBDPS cases. Her recent research involving the Centers for Birth Defects Research and Prevention (CBDRP) data have been descriptive and genetics studies of cloacal exstrophy, Dandy-Walker malformation and hydrocephalus.
More recently, Dr. Keppler-Noreuil has led studies of clinical characterization, genetic studies, and therapeutic interventions, namely clinical drug treatment trials for somatic overgrowth and vascular malformation disorders, including Proteus syndrome and PIK3CA-related overgrowth spectrum (PROS). She and her colleagues at the National Human Genome Research Institute (NHGRI) completed a Phase 0/1 clinical drug treatment trial with an AKT1 inhibitor for Proteus syndrome, Pharmacodynamic study of Miransertib in individuals with Proteus Syndrome in the American Journal of Human Genetics in 2019. In addition, with colleagues from NHGRI, Cambridge University and University of Dijon, they completed and published results of an open-label drug treatment trial for PROS, including patients with CLOVES syndrome: Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum in Genetics in Medicine in 2019. Her published studies of PROS and Proteus syndrome comprise descriptive analyses of craniofacial abnormalities, cardiac, risk factors for thromboembolism, and prevalence and complications of vascular malformations and tumors.
Denise Adams, MD
Co - Director, Vascular Anomalies Center - Boston Children's Hospital
Dr. Denise Adams is a pediatric oncologist in practice at Boston Children's Hospital. Of key interest to Dr. Adams, as an oncologist, is the improvement in care of patients with complex vascular anomalies. Dr. Adams describes her philosophy of care as this . "Since my first high school biology class, I have wanted to be a physician and since residency my passion has been the care of chronically ill children. In fellowship, I found a new passion and goal...to care for children and young adults with vascular anomalies. This was a spectrum of diseases with limited treatment options and high morbidity that needed the care of physicians with keen interest in discovery to improve their outcomes. This is my mission."